The Association Between Erythropoiesis Resistance Index and Clinical Outcomes in Hemodialysis Patients: A Nationwide Study.

ABSTRACT: Background: Although erythropoiesis-stimulating agent (ESA) therapy is fundamental for correcting anemia, excessive ESA administration is associated with increased risks. This study aimed to investigate the impact of the erythropoietin resistance index (ERI) on clinical outcomes in a population-based cohort of hemodialysis (HD) patients. Methods: This retrospective study analyzed datasets from patients who underwent periodic HD quality assessments and their claims data. Overall, we included 35,913 patients. Participants were divided into quartiles based on the ERI during the 6-month assessment period: Q1, Q2, Q3, and Q4 groups. Results: The 5-year survival rates were 68.8% (Q1), 67.8% (Q2), 66.9% (Q3), and 60.2% (Q4) (p < 0.001). Multivariable analysis showed th

SUBMITTER: Kang SH 

PROVIDER: S-EPMC12028047 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature